Hostname: page-component-5c6d5d7d68-wbk2r Total loading time: 0 Render date: 2024-08-27T15:29:16.419Z Has data issue: false hasContentIssue false

Mental Health and Addictions in Pregnancy: Feasibility and Acceptability of a Computerized Clinical Pathway and Prevalence Rates

Published online by Cambridge University Press:  27 August 2024

R. Carmona Camacho*
Affiliation:
1Psychiatry
J. Chamorro Delmo
Affiliation:
1Psychiatry
M. Alvaro Navidad
Affiliation:
2Obstetrics and ginecology, Jimenez Diaz Foundation
N. Lopez Carpintero
Affiliation:
3Obstetrics and ginecology, Tajo University Hospital
N. Estrella Sierra
Affiliation:
4Psychiatry, Infanta Elena University Hospital, Madrid, Spain
R. Guimaraes de Oliveira
Affiliation:
5Child and Adolescent Psychiatry, Hassenfeld Children’s Hospital at NYU Langone, New York, United States
M. Olhaberry Huber
Affiliation:
6Psychology, Pontificia Universidad Católica de Chile, Santiago, Chile
L. Mata Iturralde
Affiliation:
1Psychiatry
R. Álvarez García
Affiliation:
7Psychiatry, Rey Juan Carlos University Hospital, Madrid, Spain
E. Baca Garcia
Affiliation:
1Psychiatry
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Mental Health problems and substance misuse during pregnancy constitute a serious social problem due to high maternal-fetal morbidity (Cook et al, 2017; JOCG, 39(10) ,906-915) and low detection and treatment rates (Carmona et al. Adicciones. 2022;34(4):299-308)

Objectives

Our study aimed to develop and test the feasibility and acceptability of a screening and treatment clinical pathway in pregnancy, based on the combination of e-Health tools with in-person interventions and, secondly, describe the prevalence of mental illness and substance use problems in this population.

Methods

1382 pregnant women undergoing her first pregnancy visit were included in a tailored clinical pathway and sent a telematic (App) autoapplied questionnaire with an extensive battery of measures (WHO (Five) Well-Being [WHO-5],Patient Health Questionnaire [PHQ-9], General Anxiety Disorder [GAD-7], Alcohol Use Disorders Identification Test [AUDIT], Drug Abuse Screening Test [DAST], Columbia Suicide Severity Rating Scale [C-SSRS] and specifically designed questions on self-harm and psychopharmacological drugs).

Patients who did not respond to the questionnaire on their own received a counseling call.

Based on the screening results, patients were classified into five groups according to severity (Figure 1) and assigned a specific action pathway (Figure 2) that included a range of intervention intensity that goes from an individual psychiatric appointment to no intervention.

Results

Of the 1382 women included in the clinical pathway, 565(41%) completed the evaluation questionnaires. Of these, 205 (36%) were screened as positive (Grades III,IV or V. Table 1) and 3(0.5%) were classified as needing urgent care. Of the patients offered on-line groups (100), 40% (40) were enrolled in them.Table 1:

Grade distribution of those screened as positives

Grade III97 (17,2%)
Grade IV105 (18,6%)
Grade V3 (0,5%)

Concerning prevalence rates, 73 (12,9%) patients endorsed at least moderate anxiety according to GAD-7 (≥10), 65 (11,5%) endorsed at least moderate depression according to PHQ-9 (≥ 10), 17 were positive on DAST (3%) and 63 (11%) patients scored above the threshold in AUDIT-C(≥ 3) for alcohol use.

Image:

Image 2:

Conclusions

High prevalence rates suggest that effective detection and treatment mechanisms should be integrated into usual care. The use of standardized clinical pathways can help with this aim, allowing better clinical management and referral to treatment, but still face challengues to increase retention. The use of e-health tools offers the opportunity to improve accessibility and therapeutic outcomes through online interventions.

Disclosure of Interest

None Declared

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.